List of Excipients in Branded Drug NORA BE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Teva Pharmaceuticals Inc	NORA BE	norethindrone	0480-3475	LACTOSE
Teva Pharmaceuticals Inc	NORA BE	norethindrone	0480-3475	MAGNESIUM STEARATE
Teva Pharmaceuticals Inc	NORA BE	norethindrone	0480-3475	POVIDONE
Teva Pharmaceuticals Inc	NORA BE	norethindrone	0480-3475	STARCH, CORN
Actavis Pharma Inc	NORA BE	norethindrone	52544-629	LACTOSE

NORA-BE Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

NORA-BE is a norethindrone 0.35 mg progestin-only oral contraceptive supplied as a 28-tablet regimen. Its public labeling identifies a relatively simple immediate-release tablet platform, creating opportunities in excipient substitution, lactose-free reformulation, improved tablet robustness, packaging, and contract manufacturing. The strongest commercial opportunities are likely in generic or authorized-generic supply, private-label distribution, and differentiated patient-friendly formulations rather than in patent exclusivity.

What is NORA-BE and how is it formulated?

NORA-BE contains norethindrone, a synthetic progestin, at 0.35 mg per tablet. Each 28-day pack contains active tablets rather than the hormone-free placebo sequence used in many combined oral contraceptive products. The product is administered continuously, with one tablet taken daily at approximately the same time.[1]

Public product labeling identifies the following inactive ingredients:

Component	Functional role
Lactose monohydrate	Diluent and tablet mass builder
Pregelatinized starch	Binder, disintegrant, and compressibility aid
Magnesium stearate	Lubricant
Norethindrone	Active pharmaceutical ingredient

NORA-BE is an immediate-release oral tablet. The formulation does not depend on a complex delivery system, modified-release matrix, enteric coating, lipid system, or specialized polymer platform.[1]

Why the 0.35 mg dose affects excipient selection

Norethindrone represents a small fraction of total tablet weight. At this dose, manufacturing performance depends on uniform distribution of the active ingredient through the powder blend and consistent tablet compression. The principal technical risks are:

1. Content-uniformity failure caused by segregation or inadequate blending.
2. Variable disintegration caused by lubricant overmixing or excessive compression.
3. Tablet friability and chipping during high-speed packaging.
4. Dissolution changes following excipient substitution.
5. Stability effects from moisture, heat, and excipient impurities.

The formulation therefore needs an excipient system that supports low-dose homogeneity without creating excessive tablet weight or slowing drug release.

What excipient strategy is used in NORA-BE?

The existing formulation uses a conventional lactose-starch-magnesium stearate platform. This is commercially attractive because the components are widely available, inexpensive, and supported by extensive oral solid-dose manufacturing experience.

Lactose monohydrate

Lactose functions primarily as a diluent. It contributes bulk to a low-dose tablet and can support acceptable tablet hardness and powder flow when paired with starch.

The main commercial limitations are:

• Suitability concerns for patients avoiding lactose.
• Potential incompatibility with certain moisture-sensitive formulations.
• Dependence on reliable particle-size and grade control.
• Possible supplier variability affecting flow, blend uniformity, and compression.

A reformulator could evaluate spray-dried lactose, anhydrous lactose, or a lactose-free diluent system. The choice would need to preserve dissolution, tablet weight, hardness, friability, and content uniformity.

Pregelatinized starch

Pregelatinized starch performs several functions. It can improve binding during compression and promote tablet breakup after administration. Multifunctional excipients reduce formulation complexity and can lower manufacturing cost.

Its performance depends on:

• Moisture content.
• Degree of pregelatinization.
• Particle size.
• Mixing energy.
• Compression force.
• Storage conditions.

A replacement with native starch, partially pregelatinized starch, microcrystalline cellulose, or a co-processed excipient could alter tablet hardness and disintegration. Any substitution would require comparative dissolution and stability work.

Magnesium stearate

Magnesium stearate reduces friction during tablet compression and ejection. It is effective at low concentrations but can impair wetting and slow dissolution if overused or mixed for too long.

A robust manufacturing process should control:

• Lubricant concentration.
• Lubricant particle size.
• Order of addition.
• Blend time.
• Shear exposure.
• Compression force.

Potential alternatives include sodium stearyl fumarate or other pharmaceutical lubricants. The commercial rationale for substitution would be strongest where a manufacturer seeks faster dissolution, improved process robustness, or a formulation free from magnesium stearate.

What are the most attractive NORA-BE formulation opportunities?

Lactose-free NORA-BE equivalent

A lactose-free version is the clearest excipient-led opportunity. The current public formulation uses lactose monohydrate, while a replacement platform could use microcrystalline cellulose, mannitol, dibasic calcium phosphate, or a co-processed filler-binder.

A lactose-free product could support:

• Retail pharmacy differentiation.
• Institutional purchasing requirements.
• Private-label contraceptive programs.
• Patient preference marketing.
• International markets with different excipient expectations.

The formulation must avoid creating a new clinical claim unless supported by appropriate regulatory evidence. The commercial message would likely focus on excipient composition and tolerability rather than therapeutic superiority.

Direct-compression formulation

A direct-compression platform could reduce manufacturing steps, equipment requirements, and cycle time. Co-processed excipients may improve flow and compactibility while reducing dependence on separate binder and disintegrant optimization.

The main risk is the low norethindrone dose. Direct compression can increase segregation risk if the active and excipient particles differ materially in density, size, or morphology. Ordered mixing, particle engineering, geometric dilution, or granulated active premixes may be required.

Improved tablet robustness

NORA-BE is supplied in a daily-use 28-tablet format. Tablets must withstand bottling, blistering, shipping, and repeated patient handling. A stronger tablet could reduce:

• Chipping.
• Capping.
• Powdering.
• Packaging rejects.
• Complaint rates.
• Breakage during transport.

An excipient system using microcrystalline cellulose, a stronger binder, or a co-processed filler could improve mechanical strength. The tradeoff is that higher hardness can delay disintegration and dissolution.

Lower tablet weight

A lower-weight tablet could improve swallowability and reduce packaging volume. This opportunity is technically constrained by the need to maintain low-dose content uniformity. High-functionality excipients could reduce total mass while maintaining compression and disintegration performance.

The opportunity is more relevant for:

• Unit-dose blister packaging.
• Travel packs.
• Adolescent and young-adult products.
• Subscription dispensing.
• Compact emergency or institutional kits.

Alternative lubricant system

Replacing magnesium stearate may offer a differentiated formulation profile, but the commercial value is lower than for a lactose-free platform unless the alternative materially improves dissolution or manufacturability.

Sodium stearyl fumarate is one potential candidate because it can provide lubrication with different hydrophobicity and mixing behavior. The reformulator would need to evaluate ejection force, tablet hardness, friability, dissolution, and stability.

How should a lactose-free NORA-BE formulation be designed?

A practical lactose-free screening matrix would compare several diluent-binder systems rather than simply replacing lactose one-for-one.

Candidate platform	Potential advantage	Main risk
Microcrystalline cellulose plus starch	Strong compaction and broad regulatory familiarity	Higher tablet weight and possible slow disintegration
Mannitol plus crospovidone	Good mouthfeel and rapid breakup	Cost and possible sensitivity to compression conditions
Spray-dried mannitol	Flow and direct-compression performance	Supplier and grade dependence
Dibasic calcium phosphate	High density and good flow	Potential dissolution and compatibility changes
Co-processed filler-binder	Simplified process and robust compression	Higher excipient cost and supplier concentration
Starch-based lactose-free system	Familiar regulatory profile	Greater moisture sensitivity and variable flow

The preferred platform would be selected through a design-of-experiments program covering blend uniformity, tablet weight, hardness, friability, disintegration, dissolution, assay, related substances, and accelerated stability.

For an ANDA-level product, the formulation should remain as close as practical to the reference product's critical quality attributes. A distinct excipient system is possible, but it increases the need for comparative dissolution and process validation.

What regulatory pathway applies to NORA-BE excipient changes?

A generic NORA-BE equivalent would generally proceed through the ANDA pathway if the applicant can demonstrate pharmaceutical equivalence and bioequivalence to the applicable reference product.[2] The applicant must address:

• Active ingredient identity and strength.
• Dosage form and route.
• Labeling requirements.
• Inactive ingredients.
• Dissolution performance.
• Stability.
• Manufacturing controls.
• Bioequivalence.

FDA's Inactive Ingredient Database provides a reference point for excipients previously used in approved drug products.[3] Inclusion in the database does not eliminate the need to demonstrate that the proposed formulation is suitable for the specific dosage form and strength.

For postapproval manufacturing changes, FDA's SUPAC guidance for immediate-release solid oral dosage forms provides a framework for evaluating changes in composition, site, process, and scale.[4] A major excipient substitution could require additional dissolution testing, stability data, or other regulatory support depending on the change's level and effect.

FDA regulatory status and Orange Book considerations

NORA-BE is an FDA-regulated prescription oral contraceptive product. The Orange Book is the controlling public source for reference-listed-drug status, patent listings, exclusivity, and therapeutic-equivalence information.[5]

For commercial planning, an applicant should distinguish among:

• The branded NORA-BE product.
• The applicable reference-listed drug.
• Other approved norethindrone 0.35 mg tablets.
• Authorized-generic arrangements.
• Private-label products supplied under different National Drug Codes.

A reformulated product that changes excipients does not receive new chemical-entity exclusivity. Its commercial protection would generally depend on regulatory approval timing, manufacturing scale, supply reliability, trademarks, distribution contracts, and any separately protectable formulation or process technology.

What patents protect NORA-BE and its excipient platform?

The public commercial value of NORA-BE is unlikely to depend on a modern formulation-patent estate. Norethindrone 0.35 mg oral tablets are based on an established active ingredient and conventional immediate-release technology.

Relevant protection categories include:

Protection category	Relevance to NORA-BE
Active-ingredient patents	Likely limited for an established norethindrone product
Formulation patents	Potentially relevant only if a new excipient system or delivery profile is claimed
Method-of-use patents	May cover contraceptive use, but broad legacy claims are unlikely to provide a strong current barrier
Manufacturing patents	Could protect blending, granulation, compression, or impurity-control processes
Packaging patents	Could cover calendar packaging, adherence systems, or unit-dose presentation
Trademarks	May protect the NORA-BE brand identity
Trade secrets	Can protect blend order, process parameters, supplier specifications, and control strategy

A new lactose-free or high-performance formulation could support narrow formulation claims if it demonstrates a defined composition and a measurable technical advantage. Patent strength would depend on claim breadth, prior art, enablement, obviousness risk, and the ability to link the formulation to a commercially meaningful product.

When does NORA-BE lose exclusivity and what is the Paragraph IV risk?

NORA-BE is not a biologic and does not create biosimilar exclusivity issues. The relevant competitive pathway is generic substitution through ANDAs, not a 351(k) biosimilar application.

For an established norethindrone tablet, generic-entry risk is structurally high because:

• The active ingredient is well known.
• The dosage form is conventional.
• Manufacturing technology is widely available.
• The product does not require a complex delivery device.
• Multiple oral contraceptive suppliers operate in the U.S. market.

Paragraph IV litigation would become relevant only if an applicant certifies that a listed patent is invalid, unenforceable, or not infringed. The commercial impact would depend on the specific Orange Book listings and the timing of any 30-month stay, preliminary injunction, settlement, or launch at risk.[2,5]

A conventional excipient substitution would not normally create a durable exclusivity period. A new formulation patent could create a litigation issue, but only if the relevant patent is listed or otherwise enforceable against the proposed product and the applicant's product falls within the claims.

Which companies are challenging NORA-BE and what is the litigation status?

Publicly available commercial and regulatory records do not establish a major current patent-litigation barrier specific to the conventional NORA-BE excipient platform. The relevant competitive field consists primarily of manufacturers of norethindrone 0.35 mg tablets and other progestin-only contraceptives.

Competitive pressure can arise through:

• ANDA approvals.
• Authorized generics.
• Pharmacy benefit manager contracting.
• State and federal contraceptive procurement.
• Manufacturer shortages.
• Private-label pharmacy products.
• Alternative progestin-only pills.
• Nonoral contraceptive products.

The absence of a complex device or biologic manufacturing process lowers technical entry barriers. Supply continuity, FDA compliance, validated low-dose blending, and customer contracting may matter more than patent litigation.

What commercial opportunities exist for NORA-BE excipients?

Generic and authorized-generic supply

A manufacturer with a validated lactose-free or cost-optimized formulation could pursue an ANDA or supply arrangement with a branded or private-label distributor. The value proposition would depend on approval timing, manufacturing cost, and supply reliability.

Private-label contraception

Pharmacies, telehealth providers, health plans, and public-health programs may purchase norethindrone tablets under private-label or contract-manufactured arrangements. A differentiated excipient profile can support product selection where procurement specifications include allergen, dietary, or excipient requirements.

Institutional and government procurement

Institutional buyers often prioritize:

• Low acquisition cost.
• Reliable fill rates.
• Long dating.
• Simple storage.
• Packaging efficiency.
• Documented supply-chain controls.

An excipient platform that improves yield, reduces rejects, or supports high-speed packaging can create more value than a consumer-facing formulation claim.

Contract development and manufacturing

The product is suitable for a contract development and manufacturing organization with capabilities in:

• Low-dose oral solid formulation.
• Content-uniformity control.
• Direct compression or dry granulation.
• Blister and bottle packaging.
• Analytical method transfer.
• ANDA support.
• Multi-market registration.

A supplier that can provide both lactose-containing and lactose-free platforms could serve multiple customers without developing a wholly different product architecture.

Packaging and adherence products

Because NORA-BE is taken daily in a continuous 28-day cycle, calendarized blister packaging can improve dosing organization. Packaging differentiation may include:

• Day-of-week labeling.
• Compact travel packs.
• Unit-dose blister cards.
• Tamper-evident formats.
• Multilingual labeling.
• Digital refill integration.

Packaging does not replace the need for pharmaceutical equivalence, but it can improve commercial positioning in channels where adherence and convenience affect purchasing decisions.

How does NORA-BE compare with other progestin-only contraceptives?

NORA-BE competes with other norethindrone 0.35 mg tablets and with newer progestin-only products such as drospirenone tablets. The principal differences are not only excipient-based.

Attribute	NORA-BE-type norethindrone tablet	Newer progestin-only tablet
Dosage form	Immediate-release tablet	Immediate-release tablet
Active ingredient	Norethindrone 0.35 mg	Product-specific progestin
Regimen	Continuous 28-day dosing	Product-specific schedule
Manufacturing complexity	Low to moderate	Low to moderate
Patent risk	Generally lower for legacy platform	Potentially higher for newer active or formulation
Excipient differentiation	Meaningful for lactose-free and process optimization	May be more constrained by newer product claims
Generic-entry risk	High for mature products	Depends on patents and exclusivity

NORA-BE's main competitive advantages are familiarity, established manufacturing processes, and the mature generic supply base. Its weaknesses are limited differentiation and likely price competition.

What generic launch scenarios exist for NORA-BE?

Low-cost conventional launch

A manufacturer could reproduce the established excipient platform and compete primarily on price, supply, and distribution. This is the fastest route but offers limited differentiation.

Lactose-free launch

A lactose-free formulation could command preference-based demand from pharmacies, telehealth channels, and institutional buyers. The commercial benefit would depend on whether the product can maintain competitive pricing.

Premium adherence package

A manufacturer could combine a conventional tablet with calendarized packaging and subscription fulfillment. The premium would come from packaging and service rather than the tablet itself.

Dual-source manufacturing strategy

A company could maintain one formulation with multiple qualified excipient suppliers and manufacturing sites. This approach reduces shortage exposure and may appeal to public-sector and large-distributor customers.

Key Takeaways

• NORA-BE is a norethindrone 0.35 mg, 28-tablet, progestin-only oral contraceptive.
• Its public formulation uses lactose monohydrate, pregelatinized starch, and magnesium stearate.
• The most credible excipient opportunity is a lactose-free immediate-release tablet.
• Low-dose content uniformity is the principal technical challenge.
• Direct compression, improved tablet robustness, and alternative lubricant systems are secondary opportunities.
• Generic competition is likely to be driven more by manufacturing economics, supply reliability, and contracting than by patent barriers.
• NORA-BE is not subject to biosimilar competition.
• Any new formulation would need to address ANDA requirements, inactive-ingredient suitability, dissolution, stability, and bioequivalence.
• Packaging, private-label supply, institutional procurement, and contract manufacturing offer practical commercial channels.
• Patent value would be strongest for a demonstrably differentiated formulation or manufacturing process, not for the conventional tablet platform.

FAQs

Is NORA-BE lactose-free?

No. Public labeling identifies lactose monohydrate as an inactive ingredient.[1] A lactose-free equivalent would require a different excipient system and regulatory assessment.

Can microcrystalline cellulose replace lactose in NORA-BE?

Potentially. Microcrystalline cellulose can provide dilution and binding, but the replacement must be optimized for blend uniformity, tablet hardness, disintegration, dissolution, and stability.

Does NORA-BE have biosimilar competition?

No. NORA-BE is a small-molecule oral tablet. Competitive products would generally use the generic-drug pathway rather than the biosimilar pathway.

Could a new NORA-BE formulation receive a formulation patent?

Yes, if the formulation has patentable composition or process features and satisfies novelty, nonobviousness, enablement, and written-description requirements. A simple excipient substitution would face a higher obviousness risk.

What is the best commercial differentiator for a NORA-BE generic?

A lactose-free tablet combined with reliable supply, competitive pricing, and efficient 28-day packaging is the most practical differentiation strategy. A complex delivery system would add development cost without an obvious commercial requirement.

References

1. DailyMed. (n.d.). NORA-BE: Norethindrone tablet prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (2024). Abbreviated new drug application (ANDA) process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

3. U.S. Food and Drug Administration. (2024). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=inactiveingredientdatabase

4. U.S. Food and Drug Administration. (1995). SUPAC-IR: Immediate release solid oral dosage forms: Scale-up and post-approval changes. https://www.fda.gov/regulatory-information

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/_久久爱